三年是持续性临床缓解预防狼疮性肾炎肾功能受损与损伤累积的最小有效时长
该研究纳入293例经活检证实的狼疮性肾炎患者,中位随访15.7年,评估持续性临床缓解(sCR)预防损伤累积(SDI增加)和肾功能受损(IKF)的最小有效时长。结果显示,sCR至少持续3年可预防SDI增加(变化百分比=-41.1%;P=.003)和IKF(风险比=0.10;P<.001)。
要点
- sCR至少持续3年可预防SDI增加,变化百分比为-41.1%(P=.003)。
- sCR至少持续3年可预防IKF,风险比为0.10(P<.001)。
- 从未达到sCR者10、20、25年无IKF生存率分别为87%、68%、40%,sCR≥3年者为99%、96%、91%(P<.001)。
核心结论
- 三年是sCR保护狼疮性肾炎患者免于发生IKF和损伤累积的最小持续时长。
研究设计与样本
- 纳入293例经活检证实的狼疮性肾炎患者,每年至少随访两次,定期收集临床变量,采用对数线性回归和时间依赖Cox比例风险模型评估sCR的最小有效时长。
主要发现
- 293例患者中位随访15.7(10.4-22.9)年,84.3%达到sCR,sCR持续8.7(5.4-13.1)年。
- 末次观察时,从未达到sCR者SDI增加高于达到sCR者(中位数2[1-2.5] vs 1[0-1.5];P<.001)。
- sCR至少持续3年可预防SDI增加(变化百分比=-41.1%;P=.003)。
- IKF分析仅纳入随访最长者,224例观察≥10年,其中50例(22.3%)发生IKF;sCR至少持续3年可预防IKF(风险比=0.10;P<.001)。
- 从未达到sCR者10、20、25年无IKF生存率分别为87%、68%、40%,sCR至少3年者为99%、96%、91%(P<.001)。
关键数值与推荐
- sCR定义为估算肾小球滤过率>60 mL/min/1.73 m2、蛋白尿<0.5 g/24 h且临床系统性红斑狼疮疾病活动指数为0持续至少1年。
- IKF定义为估算肾小球滤过率<60 mL/min/1.73 m2持续至少3个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the minimum effective duration of remission preventing damage accrual (Systemic Lupus International Collaborating Clinics damage index [SDI]) and impaired kidney function (IKF: estimated glomerular filtration rate of <60 mL/min/1.73 m2 for at least 3 months) in active lupus nephritis (LN). METHODS: Patients with biopsy-proven LN followed up at least twice yearly were enrolled; clinical variables were collected regularly. Sustained clinical remission (sCR) was defined as estimated glomerular filtration rate of >60 mL/min/1.73 m2, proteinuria of <0.5 g/24 h and clinical systemic lupus erythematosus disease activity index of 0 for at least 1 year. Log-linear regression and a time-dependent Cox proportional hazard model were used to assess the minimum duration of sCR capable of preventing SDI increase and IKF development. RESULTS: In total, 293 patients with LN were included (median follow-up: 15.7 [10.4-22.9] years) of whom 84.3% achieved sCR lasting 8.7 (5.4-13.1) years. At last observation, the increase in SDI was higher in patients who never achieved sCR (median: 2 [1-2.5] vs 1 [0-1.5]; P < .001). A minimum duration of 3 years of sCR prevented SDI increase (% change = -41.1%; P = .003). The analysis on IKF involved only patients with the longest follow-up; 224 patients had ≥10 years of observation. Among them, 50 (22.3%) developed IKF. A minimum duration of 3 years of sCR prevented IKF (hazard ratio = 0.10; P < .001). IKF-free survival rate at 10, 20, and 25 years was 87%, 68%, and 40% for patients who never achieved sCR and 99%, 96%, and 91% for patients with at least 3 years of sCR, respectively (P < .001). CONCLUSIONS: Three years is the minimum duration of sCR protecting against development of IKF and damage accrual in patients with LN.
引用
- Gatto M, Frontini G, Furlan C, et al. Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis. Ann Rheum Dis. 2025. PMID: 40023731. doi:10.1016/j.ard.2025.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。